{"entity":{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","aka":["JITC","J Immunother Cancer"],"tldr":"SITC's fully open-access journal: checkpoint-inhibitor and cell-therapy trials, immune-related toxicity management guidelines and immunotherapy biomarkers.","summary":"Fully open access, published by BMJ on behalf of the Society for Immunotherapy of Cancer. Publishes phase 1 and 2 immunotherapy trials, SITC clinical practice guidelines on immune-related adverse events and biomarkers, and the SITC annual meeting abstracts. Strong on real-world toxicity and combination strategies.","asOf":"2026-09-09","links":[{"label":"SITC","url":"https://www.sitcancer.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sitc"],"pathways":[],"terms":["immune-checkpoint","irae","biomarker"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMJ Group","url":"https://jitc.bmj.com","issn":"2051-1426","scope":"immunotherapy","access":"open-access","founded":2013,"impactFactor":{"value":10.3,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Journal for ImmunoTherapy of Cancer","JITC","J Immunother Cancer"],"society":"Society for Immunotherapy of Cancer"},"route":"/journals/jitc/","neighbours":{"institution":[{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/"}],"term":[{"id":"biomarker","kind":"term","name":"Biomarker","route":"/terms/biomarker/"},{"id":"immune-checkpoint","kind":"term","name":"Immune checkpoint","route":"/terms/immune-checkpoint/"},{"id":"irae","kind":"term","name":"Immune-related adverse events (irAEs)","route":"/terms/irae/"}],"person":[{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","route":"/people/ezra-cohen/"},{"id":"john-kennedy","kind":"person","name":"John Kennedy","route":"/people/john-kennedy/"},{"id":"yoon-seung-kew","kind":"person","name":"Yoon Seung-kew","route":"/people/yoon-seung-kew/"}],"paper":[{"id":"paper-durvalumab-endometrial-j-immunother-cancer-2021","kind":"paper","name":"Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial","route":"/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/"},{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/"},{"id":"paper-merino-j-immunother-cancer","kind":"paper","name":"Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project","route":"/key-papers/paper-merino-j-immunother-cancer/"},{"id":"paper-wagner-j-immunother-cancer","kind":"paper","name":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","route":"/key-papers/paper-wagner-j-immunother-cancer/"},{"id":"paper-nct05877430-j-immunother-cancer-2026","kind":"paper","name":"Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma","route":"/key-papers/paper-nct05877430-j-immunother-cancer-2026/"},{"id":"paper-checkmate-915-j-immunother-cancer-2025","kind":"paper","name":"Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915","route":"/key-papers/paper-checkmate-915-j-immunother-cancer-2025/"},{"id":"paper-keynote-017-j-immunother-cancer-2021-update","kind":"paper","name":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","route":"/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/"},{"id":"paper-nct05081609-j-immunother-cancer-2022","kind":"paper","name":"TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer","route":"/key-papers/paper-nct05081609-j-immunother-cancer-2022/"},{"id":"paper-javelin-merkel-200-j-immunother-cancer-2018-update","kind":"paper","name":"Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial","route":"/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/"}]}}